Dexcom touts A1C reductions with for MDI patients using CGM
Dexcom Inc. (NSDQ:DXCM) said late last week that data from a study of patients undergoing multiple daily injections of insulin to treat diabetes showed that its continuous glucose monitoring systems can reduce overall A1C by nearly 1% on average.
The data comes from 2 cohorts from the Diamond study exploring the use of CGMs with patients on MDIs, and indicated that DexCom CGM users achieved a 0.9% reduced A1C level on average at 24 weeks, while standard of care treatments showed reductions of 0.5%
Results also indicated strong adherence to CGM in adults with both type 1 and 2 diabetes regardless of age, education or numeracy, with 93% using the CGM more than 6 days a week at 6-months. CGM users had incrased rtime in range, with cases of hypoglycemia and hyperglycemia decreasing.
“This new data represents another important milestone in a blockbuster year for the advancement of diabetes management. As the first and only therapeutic CGM approved by Medicare for patients age 65 or older, DexCom G5 Mobile is setting a new standard of care for a wide spectrum of patients,” prez & CEO Kevin Sayer said in a press release.